Evaluation of pre-exposure vaccine effectiveness against mpox during the 2022–2023 mpox outbreak in the Madrid region (Spain): a test-negative design

Author:

Barbas del Buey José FranciscoORCID,Íñigo Martínez JesúsORCID,Alonso García Marcos,Aragón Peña Andrés,Montero Morales Laura,Arce Arnáez AraceliORCID

Abstract

IntroductionAn appropriate vaccination approach is critical to control the current outbreak of mpox but there is little research providing information on its effectiveness, particularly under circumstances of limited vaccine availability.MethodsPre-exposure vaccination campaign in the Madrid region, with the modified vaccinia Ankara-Bavarian Nordic was indicated in the risk groups from 18 July 2022.To evaluate the vaccine effectiveness (VE) of a dose of third-generation smallpox vaccine against mpox in the context of pre-exposure prophylaxis, a population-based indirect cohort study (Broome method) also known as test-negative design (TND) was conducted in the Madrid region (6 751 251 inhabitants). Logistic regression was used to obtain the adjusted VE in the TND with its time–response relationship and for the sensitivity analysis the conditional logistic regression for matched case–control groups.ResultsBy epidemiological surveillance, 1690 suspected episodes of mpox were detected of which 799 were cases and 891 controls.The overall adjusted effectiveness of the pre-exposure vaccination against mpox considering an induction period of 14 days, was 86.4% (95% CI 62.2% to 95.1%). VE increases, with a statistically significant time–response effect, being greater than 77.4% with a 95% confidence level from week 7. The VE at eighth week of vaccination was 99% (95% CI 81.7% to 99.9%).ConclusionsThe effectiveness of single-dose pre-exposure vaccination against mpox seems very high. Therefore, it appears as a reliable measure to minimise the spread of mpox.The progressive increase in the effectiveness could justify the delay in the administration of the second dose in situations of shortage of vaccines or prioritisation in the vaccination of the maximum number of subjects at risk.Further studies evaluating the long-term effectiveness of the full vaccination would be appropriate.

Publisher

BMJ

Reference47 articles.

1. World Health Organization . Multi-country outbreak of Mpox, External situation report#14- 19 January 2023. 2023. Available: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-14--19-january-2023

2. World Health Organization . Segunda Reunión del Comité de Emergencias del Reglamento Sanitario Internacional (2005) (RSI) Sobre El Brote de Viruela Símica en Varios Países [Second meeting of the emergency committee of the International health regulations (2005) (IHR) on the outbreak of Monkeypox in several countries]. n.d. Available: https://bit.ly/3P0IvMD

3. A large multi-country outbreak of Monkeypox across 41 countries in the WHO European region;Vaughan;Euro Surveill,2022

4. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022;Iñigo Martínez;Euro Surveill,2022

5. Ministerio de Sanidad . Alerta sobre infección de viruela del mono en España y otros países no endémicos. Informe de situación 2 de noviembre de 2022 [Alert on monkeypox infection in Spain and other non-endemic countries. 2022. Available: https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/alertaMonkeypox/docs/Informe_de_situacion_MPX_20221102.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3